Barclays PLC Has $7.91 Million Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Barclays PLC raised its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 496.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 174,061 shares of the company's stock after acquiring an additional 144,883 shares during the period. Barclays PLC owned approximately 0.33% of Janux Therapeutics worth $7,907,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of JANX. Plato Investment Management Ltd increased its stake in Janux Therapeutics by 18.7% in the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company's stock valued at $54,000 after acquiring an additional 187 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock worth $87,000 after purchasing an additional 339 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of Janux Therapeutics by 61.1% in the 2nd quarter. Amalgamated Bank now owns 970 shares of the company's stock valued at $41,000 after purchasing an additional 368 shares in the last quarter. Summit Securities Group LLC bought a new position in shares of Janux Therapeutics in the 2nd quarter valued at $29,000. Finally, Zacks Investment Management raised its holdings in shares of Janux Therapeutics by 8.7% during the 3rd quarter. Zacks Investment Management now owns 42,133 shares of the company's stock worth $1,914,000 after buying an additional 3,360 shares in the last quarter. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Stock Performance

Shares of NASDAQ:JANX opened at $59.61 on Wednesday. Janux Therapeutics, Inc. has a 52 week low of $7.79 and a 52 week high of $71.71. The firm has a market cap of $3.13 billion, a PE ratio of -50.95 and a beta of 3.29. The firm's fifty day moving average is $53.37 and its 200-day moving average is $46.92.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The company had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. The company's revenue was down 82.6% on a year-over-year basis. Sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Wall Street Analysts Forecast Growth

JANX has been the topic of several research analyst reports. Leerink Partners raised their price objective on Janux Therapeutics from $79.00 to $91.00 and gave the company an "outperform" rating in a research note on Tuesday, December 3rd. HC Wainwright raised their price target on shares of Janux Therapeutics from $63.00 to $70.00 and gave the company a "buy" rating in a research note on Tuesday, December 3rd. UBS Group initiated coverage on shares of Janux Therapeutics in a report on Thursday, October 24th. They set a "buy" rating and a $69.00 price target on the stock. Scotiabank increased their price objective on shares of Janux Therapeutics from $42.00 to $62.00 and gave the company a "sector perform" rating in a research note on Wednesday, December 4th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $200.00 target price on shares of Janux Therapeutics in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Janux Therapeutics currently has a consensus rating of "Buy" and an average target price of $89.90.

Insider Buying and Selling

In other Janux Therapeutics news, Director Ra Capital Management, L.P. bought 1,200,000 shares of the stock in a transaction on Friday, October 18th. The stock was acquired at an average cost of $44.75 per share, for a total transaction of $53,700,000.00. Following the completion of the acquisition, the director now owns 9,317,246 shares in the company, valued at $416,946,758.50. This trade represents a 14.78 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Ventures Xi L.P. Avalon sold 49,231 shares of the business's stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $46.45, for a total value of $2,286,779.95. Following the completion of the transaction, the insider now directly owns 6,926 shares in the company, valued at approximately $321,712.70. This trade represents a 87.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 192,032 shares of company stock valued at $9,512,515 over the last quarter. Insiders own 29.40% of the company's stock.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.